Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended CHLORIDE ICU fluid strategy study
ACTRN12614000866606Phase 4Completed
- Sponsor
- Austin Health
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of plasma-lyte, lactated ringer's solution, human albumin, sodium chloride and gelatin in acute kidney failure (AKF) (2 arms), sponsored by Austin Health. Primary endpoint: Incidence of acute kidney injury. Started Aug 2007; status: completed.
02
Drugs
plasma-lytelactated ringer's solutionhuman albuminsodium chloridegelatin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12614000866606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000866606.